Catharanthine alkaloids are noncompetitive antagonists of muscle-type nicotinic acetylcholine receptors.
Hugo R Arias, Dominik Feuerbach, Katarzyna M Targowska-Duda, Krzysztof Jozwiak
Neurochemistry International September 1, 2010 DOI: 10.1016/j.neuint.2010.05.007 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro experimental study Peer reviewed |
|---|---|
| Population | TE671-halpha1beta1gammadelta cells expressing muscle nicotinic acetylcholine receptors; Torpedo AChR preparations |
| Interventions | Ibogaine vincristine vinblastine phencyclidine |
| Keywords | Neuropharmacology Receptor inhibition |
| Citations | 9 |
| Key findings | Catharanthine alkaloids noncompetitively inhibit muscle nicotinic acetylcholine receptors by blocking the ion channel and promoting desensitization, with ibogaine and PCP binding to overlapping sites in the desensitized receptor channel. |
Abstract
We compared the interaction of several catharanthine alkaloids including, ibogaine, vincristine, and vinblastine, with that for the noncompetitive antagonist phencyclidine (PCP) at muscle nicotinic acetylcholine receptors (AChRs) in different conformational states. The results established that catharanthine alkaloids: (a) inhibit, in a noncompetitive manner, (+/-)-epibatidine-induced Ca(2+) influx in TE671-halpha1beta1gammadelta cells with similar potencies (IC(50)=17-25microM), (b) inhibit [(3)H]TCP binding to the desensitized Torpedo AChR with higher affinity compared to the resting AChR, and (c) enhance [(3)H]cytisine binding to resting but activatable Torpedo AChRs, suggesting desensitizing properties. Interestingly, PCP inhibits [(3)H]ibogaine binding to the AChR in a steric fashion. This is corroborated by additional docking experiments indicating that the amino groups of neutral ibogaine form hydrogen bonds with the serine ring (position 6'), a location shared with PCP. Since protonated ibogaine forms a salt bridge with one of the acidic residues at the outer ring (position 20'), this ligand could be first attracted to the entrance of the channel by electrostatic interactions. Our data indicate that the catharanthine moiety is a minimum structural requirement for AChR inhibition including, ion channel blocking and desensitization, and that ibogaine and PCP bind to overlapping sites in the desensitized AChR ion channel.
Citations in the library
Cited by 4
- Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? Pharmacology & Therapeutics February 1, 2018
- Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states. The international journal of biochemistry & cell biology September 1, 2010
- Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states. The international journal of biochemistry & cell biology September 1, 2011
- Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites. The international journal of biochemistry & cell biology May 27, 2015
Cites 5
- Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine Journal of Pharmacology and Experimental Therapeutics 1999
- Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology March 1, 2002
- 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Annals of the New York Academy of Sciences September 1, 2000
- Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Molecular Pharmacology 1997
- Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European Journal of Pharmacology May 1, 2004